Get the Daily Brief
Latest Biotech News
Scripps Research Identifies Human Proteins Critical for SARS-CoV-2 Replication
Scientists at Scripps Research conducted a comprehensive siRNA screen that pinpointed key human host proteins exploited by SARS-CoV-2 during various infection stages. The study revealed 59...
Novartis Deepens Collaboration With Argo Biopharma on Cardiovascular RNA Therapies
Novartis has expanded its partnership with Argo Biopharma through a multi-asset licensing and options deal valued up to $5.2 billion, focusing on small interfering RNA (siRNA) candidates targeting...
Atlas Venture Raises $400 Million to Support Portfolio Biotechs
Atlas Venture, a key player in biotech venture capital, announced the closing of a $400 million Opportunity Fund aimed at backing existing portfolio companies. This third fund follows a $450...
FDA Enhances Transparency with Real-Time Release of Drug Rejection Letters
The U.S. Food and Drug Administration (FDA) has committed to unprecedented transparency by pledging to publish complete response letters (CRLs) to drug developers at the time they are issued. This...
BioNTech and Duality Biologics' HER2 Antibody-Drug Conjugate Surpasses Roche in Phase 3 Breast Cancer Trial
In a significant oncology breakthrough, BioNTech and its partner Duality Biologics demonstrated that their HER2-targeting antibody-drug conjugate (ADC), trastuzumab pamirtecan, surpassed Roche’s...
Radiance Biopharma Secures $1.165 Billion Deal for Bispecific Nanobody ADC Targeting Solid Tumors
Late-stage oncology capacity expansion is underscored by Radiance Biopharma’s signing of a multi-billion-dollar licensing agreement with China-based Novatim Immune Therapeutics. The pact grants...
Sanofi’s Amlitelimab Achieves Phase III Endpoints in Atopic Dermatitis but Fails to Meet Expectations
Sanofi announced that its atopic dermatitis candidate, amlitelimab, met primary endpoints in a phase III clinical trial; however, the data fell short of industry and investor expectations relative...
Charm Therapeutics Raises $80 Million to Advance Next-Generation Menin Inhibitor for Leukemia
Charm Therapeutics secured $80 million in Series B funding led by New Enterprise Associates and DR One to propel clinical development of its menin inhibitor aimed at treating acute myeloid...
University of California San Diego Finds Spaceflight Accelerates Aging of Human Stem Cells
A study led by UC San Diego's Sanford Stem Cell Institute reveals that human hematopoietic stem and progenitor cells (HSPCs) undergo accelerated aging during spaceflight. Using AI-enabled...
Scripps Research Identifies Human Host Proteins Critical for SARS-CoV-2 Replication, Revealing New Therapeutic Targets
Scripps Research scientists conducted a comprehensive siRNA screen to pinpoint host proteins indispensable to SARS-CoV-2 infection, identifying 32 proteins critical in early viral entry and 27...
Novartis Deepens RNAi Therapeutics Portfolio with $160 Million Argo Biopharma Licensing Deal
Novartis expanded its cardiovascular RNA interference (RNAi) pipeline by entering a multi-asset licensing and option agreement with Argo Biopharma worth up to $5.2 billion. The upfront $160...
Atlas Venture Raises $400 Million Opportunity Fund to Bolster Portfolio Biotechs
Atlas Venture, a leading biotech venture capital firm, announced the close of a $400 million Opportunity Fund designed to support and advance its existing portfolio companies. This capital...
FDA Increases Transparency with Real-Time Release of Drug Rejection Letters
The FDA has taken a significant step towards regulatory transparency by committing to publish complete response letters (CRLs) immediately upon issuance to drug sponsors. This initiative follows...
Regulatory Advancements: FDA Outlines Pathways for Ultrarare Genetic Disease Therapies
The FDA unveiled the Rare Disease Evidence Principles (RDEP) program to expedite review of therapies for ultrarare genetic conditions affecting fewer than 1,000 patients in the U.S. The program...
Cancer Therapeutics Advances: Radiance Biopharma Signs $1.165B Deal for Novel Bispecific ADC
Radiance Biopharma secured global rights to a bispecific nanobody antibody-drug conjugate (ADC) targeting c-MET and EGFR, designed for solid tumor treatment, through a $1.165 billion agreement...
Notable Clinical Trial Results: BioNTech’s HER2 Antibody-Drug Conjugate Demonstrates Phase 3 Success
BioNTech and partner Duality Biologics revealed positive interim results from a phase III trial of their HER2-targeting antibody-drug conjugate (ADC) for HER2-positive breast cancer, achieving the...
Enveda Biosciences Secures $150 Million Series D to Accelerate Nature-Inspired Drug Discovery
Enveda Biosciences closed a $150 million Series D financing round, increasing its total funding to over $500 million, aimed at advancing its diverse pipeline of natural product-inspired...
Spaceflight Accelerates Aging of Human Hematopoietic Stem Cells, UC San Diego Finds
A landmark study by UC San Diego researchers revealed that human hematopoietic stem and progenitor cells (HSPCs) exhibit accelerated aging following exposure to spaceflight conditions. Using...
Novartis Commits $200 Million to Develop Arrowhead’s siRNA Therapy for Parkinson’s Disease
Novartis and Arrowhead Pharmaceuticals announced a landmark $200 million upfront licensing and collaboration deal focusing on Arrowhead’s preclinical small interfering RNA (siRNA) candidate...
Breakthrough in Mapping Human Proteins Crucial for SARS-CoV-2 Replication Unveiled
Scientists at Scripps Research have identified dozens of human host proteins critical to the replication and late stages of SARS-CoV-2 infection through an extensive genome-wide siRNA screening....